Martínez F, Martín-Luengo F, García A, Valdés M
Department of Microbiology, School of Medicine, University of Murcia, Spain.
Eur Heart J. 1995 May;16(5):687-91. doi: 10.1093/oxfordjournals.eurheartj.a060974.
Streptococcus sanguis currently accounts for one-half of viridans streptococci. Treatment has become complicated due to the increase in resistance to penicillin and cephalosporins. The aim of the study was to assess the efficacy of various antibiotics as monotherapy and in association with gentamicin, in a experimental model of infective endocarditis in rabbits. The effects were compared with a control group and a group given classical penicillin-gentamicin treatment.
Infective endocarditis was induced in 180 rabbits with a clinical isolate of Streptococcus sanguis. Treatment was started 48 h after infection, and lasted 5 days. The animals were divided into nine groups of 20 rabbits: G1, untreated controls; G2, penicillin-gentamicin; G3, clindamycin-gentamicin; G4, imipenem; G5, imipenem-gentamicin; G6, teicoplanin; G7, teicoplanin-gentamicin; G8, vancomycin and G9, vancomycin-gentamicin. Response to therapy was evaluated by mortality curves, as negative blood cultures, concentration of S. sanguis in aortic vegetations and rate of sterilization of vegetations.
Vegetation weight was significantly lower in treated groups than in controls; lower weights were found in G5, 6, and 9. G9 sterilized 75% of the vegetations. Death occurred in 25% of the control group and in 4.76% of G6 and 7. Blood cultures became negative most rapidly in G9.
Combined treatment with vancomycin-gentamicin may be highly efficacious in patients with endocarditis caused by penicillin-resistant Streptococcus sanguis. Other combinations, such as imipenem-gentamicin and teicoplanin-gentamicin, may be also advantageous.
血链球菌目前占草绿色链球菌的一半。由于对青霉素和头孢菌素耐药性的增加,治疗变得复杂。本研究的目的是在兔感染性心内膜炎的实验模型中评估各种抗生素作为单一疗法以及与庆大霉素联合使用的疗效。将这些效果与对照组和接受经典青霉素 - 庆大霉素治疗的组进行比较。
用临床分离的血链球菌诱导180只兔患感染性心内膜炎。感染后48小时开始治疗,持续5天。动物分为9组,每组20只兔:G1,未治疗的对照组;G2,青霉素 - 庆大霉素;G3,克林霉素 - 庆大霉素;G4,亚胺培南;G5,亚胺培南 - 庆大霉素;G6,替考拉宁;G7,替考拉宁 - 庆大霉素;G8,万古霉素;G9,万古霉素 - 庆大霉素。通过死亡率曲线、血培养阴性情况、主动脉赘生物中血链球菌的浓度以及赘生物的杀菌率来评估治疗反应。
治疗组的赘生物重量明显低于对照组;G5、G6和G9组的赘生物重量较低。G9组使75%的赘生物无菌化。对照组25%的动物死亡,G6组为4.76%,G7组为7%。G9组血培养转阴最快。
对于由耐青霉素血链球菌引起的心内膜炎患者,万古霉素 - 庆大霉素联合治疗可能非常有效。其他联合用药,如亚胺培南 - 庆大霉素和替考拉宁 - 庆大霉素,可能也有优势。